# Cellino Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellino-biotech

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.cellinobio.com
- Total disclosed funding: $95M
- Latest round: Series A (Nov 29, 2021)
- Investors on record: 6

## About

Cellino Biotech, Inc., based in the US, specializes in advanced regenerative medicine, developing patient-specific therapies through innovative biomanufacturing methods focused on adult autologous stem cells.Founded in 2017, Cellino Biotech, Inc. operates out of Cambridge, US, and focuses on creating personalized regenerative therapies. The company is co-founded by Nabiha Saklayen, who has a history in biotech entrepreneurship. In November 2021, Cellino raised USD 80.00 mn in a Series A funding round, which has contributed to a total amount raised of USD 80.00 mn, resulting in a valuation of approximately USD 149.712 mn.Cellino Bio specializes in advanced regenerative medicine, focusing on patient-specific therapies derived from adult autologous stem cells. Their core offerings center around the Nebula™ platform, which utilizes AI-driven optical bioprocesses to facilitate the biomanufacturing of living medicines, such as cell, tissue, and organ replacements tailored for individuals suffering from chronic degenerative diseases. This innovative technology enhances treatment experiences by providing scalable, reproducible, and precise manufacturing capabilities. The company's solutions are designed for healthcare providers and institutions, enabling expanded patient access to advanced therapies. Geographically, Cellino's products are targeted at markets in North America and Europe, where there is a growing demand for personalized regenerative medicine.Cellino’s revenue structure is primarily driven by partnerships and collaborations within the healthcare sector, particularly with hospitals and specialized clinics. The company engages in B2B transactions, supplying its Nebula™ platform and associated technologies to healthcare providers who implement these advanced therapies in their treatment offerings. Revenue is generated through the sale of technology licenses, service agreements, and potentially through direct sales of proprietary therapies. The transaction framework is designed to support scalable deployment of their systems, enabling providers to offer Cellino’s innovative treatments to their patients efficiently. While specific pricing plans for individual services or products are not disclosed, the focus remains on delivering transformative, one-time treatment solutions for chronic conditions.Following the recent Series A funding of USD 80.00 mn in November 2021, Cellino Biotech, Inc. plans to expand its machine learning, software, and hardware capabilities. The funding will also support the development of early-stage Good Manufacturing Practice (GMP) capabilities to facilitate clinical trials, with a goal to construct the first autonomous human cell foundry by 2025. The company aims to further its reach in North America and Europe, where it intends to launch new products that enhance their current offerings in personalized regenerative medicine.

## Funding rounds

- Series A, Nov 29, 2021, $80M — Khosla Ventures, Felicis Ventures, 8VC, Engine Ventures, Leaps by Bayer, Humboldt Fund
- Seed, Oct 21, 2020, $15M — Khosla Ventures, 8VC, Engine Ventures, Humboldt Fund

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed, Series A
- 8VC (https://capitalatlas.ai/funds/8vc) — Seed, Series A
- Engine Ventures (https://capitalatlas.ai/funds/engine-ventures) — Seed, Series A
- Humboldt Fund (https://capitalatlas.ai/funds/humboldt-fund) — Seed, Series A
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A